Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Activation of the NF-κB Pathway and Heterozygous Deletion of TNFAIP3 (A20) Confer Superior Survival in Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type.

Liu F, Zheng JP, Wang L, Zhao DH, Li MY, Wang YM, Liu Y, Ma J, Zeng NY, Liu HX, Liang R, Guo SP, Wang Z, Yan QG.

Am J Clin Pathol. 2019 Jul 5;152(2):243-252. doi: 10.1093/ajcp/aqz041.

PMID:
31140551
2.

A20 (TNFAIP3) deletion in Epstein-Barr virus-associated lymphoproliferative disorders/lymphomas.

Ando M, Sato Y, Takata K, Nomoto J, Nakamura S, Ohshima K, Takeuchi T, Orita Y, Kobayashi Y, Yoshino T.

PLoS One. 2013;8(2):e56741. doi: 10.1371/journal.pone.0056741. Epub 2013 Feb 13.

3.

TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma.

Schmitz R, Hansmann ML, Bohle V, Martin-Subero JI, Hartmann S, Mechtersheimer G, Klapper W, Vater I, Giefing M, Gesk S, Stanelle J, Siebert R, Küppers R.

J Exp Med. 2009 May 11;206(5):981-9. doi: 10.1084/jem.20090528. Epub 2009 Apr 20.

4.

Clinicopathologic implications of TNFAIP3/A20 deletions in extranodal NK/T-cell lymphoma.

Ahn H, Yang JM, Jeon YK, Paik JH.

Genes Chromosomes Cancer. 2018 May;57(5):231-239. doi: 10.1002/gcc.22524. Epub 2018 Feb 2.

PMID:
29380463
5.

A20/Tumor Necrosis Factor α-Induced Protein 3 in Immune Cells Controls Development of Autoinflammation and Autoimmunity: Lessons from Mouse Models.

Das T, Chen Z, Hendriks RW, Kool M.

Front Immunol. 2018 Feb 21;9:104. doi: 10.3389/fimmu.2018.00104. eCollection 2018. Review.

6.

NF-kappaB activation through the alternative pathway correlates with chemoresistance and poor survival in extranodal NK/T-cell lymphoma, nasal type.

Liu X, Wang B, Ma X, Guo Y.

Jpn J Clin Oncol. 2009 Jul;39(7):418-24. doi: 10.1093/jjco/hyp037. Epub 2009 Apr 24.

PMID:
19395464
7.

Mutations of CARD11 but not TNFAIP3 may activate the NF-kappaB pathway in primary CNS lymphoma.

Montesinos-Rongen M, Schmitz R, Brunn A, Gesk S, Richter J, Hong K, Wiestler OD, Siebert R, Küppers R, Deckert M.

Acta Neuropathol. 2010 Oct;120(4):529-35. doi: 10.1007/s00401-010-0709-7. Epub 2010 Jun 11.

PMID:
20544211
8.

TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas.

Honma K, Tsuzuki S, Nakagawa M, Tagawa H, Nakamura S, Morishima Y, Seto M.

Blood. 2009 Sep 17;114(12):2467-75. doi: 10.1182/blood-2008-12-194852. Epub 2009 Jul 16.

9.

Deletion of the TNFAIP3/A20 gene detected by FICTION analysis in classical Hodgkin lymphoma.

Nomoto J, Hiramoto N, Kato M, Sanada M, Maeshima AM, Taniguchi H, Hosoda F, Asakura Y, Munakata W, Sekiguchi N, Maruyama D, Watanabe T, Nakagama H, Takeuchi K, Tobinai K, Ogawa S, Kobayashi Y.

BMC Cancer. 2012 Oct 5;12:457. doi: 10.1186/1471-2407-12-457.

10.

Mesenchymal stem cell deficiency influences megakaryocytopoiesis through the TNFAIP3/NF-κB/SMAD pathway in patients with immune thrombocytopenia.

He Y, Xu LL, Feng FE, Wang QM, Zhu XL, Wang CC, Zhang JM, Fu HX, Xu LP, Liu KY, Huang XJ, Zhang XH.

Br J Haematol. 2018 Feb;180(3):395-411. doi: 10.1111/bjh.15034. Epub 2018 Jan 12.

PMID:
29327472
11.

MicroRNAs miR-125a and miR-125b constitutively activate the NF-κB pathway by targeting the tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20).

Kim SW, Ramasamy K, Bouamar H, Lin AP, Jiang D, Aguiar RC.

Proc Natl Acad Sci U S A. 2012 May 15;109(20):7865-70. doi: 10.1073/pnas.1200081109. Epub 2012 May 1.

12.

Mutation analysis of tumor necrosis factor alpha-induced protein 3 gene in Hodgkin lymphoma.

Etzel BM, Gerth M, Chen Y, Wünsche E, Facklam T, Beck JF, Guntinas-Lichius O, Petersen I.

Pathol Res Pract. 2017 Mar;213(3):256-260. doi: 10.1016/j.prp.2016.11.001. Epub 2016 Nov 26.

PMID:
28189285
13.

Mutations in the genes coding for the NF-κB regulating factors IκBα and A20 are uncommon in nodular lymphocyte-predominant Hodgkin's lymphoma.

Schumacher MA, Schmitz R, Brune V, Tiacci E, Döring C, Hansmann ML, Siebert R, Küppers R.

Haematologica. 2010 Jan;95(1):153-7. doi: 10.3324/haematol.2009.010157. Epub 2009 Jul 31.

14.

A20 (TNFAIP3) Alterations in Primary Intestinal Diffuse Large B-cell Lymphoma.

Fujii M, Takata K, Chuang SS, Miyata-Takata T, Ando M, Sato Y, Yoshino T.

Acta Med Okayama. 2018 Feb;72(1):23-30. doi: 10.18926/AMO/55659.

15.

The correlation of clinicopathological features and prognosis in extranodal natural killer/T cell lymphoma: a report of 42 cases in the early stage.

Zeng L, Huang W, Cao Z, Zheng B, Liu X, Guo L, Feng X.

Ann Hematol. 2019 Jun;98(6):1467-1476. doi: 10.1007/s00277-019-03643-9. Epub 2019 Mar 21.

PMID:
30895352
16.

The NF-{kappa}B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas.

Novak U, Rinaldi A, Kwee I, Nandula SV, Rancoita PM, Compagno M, Cerri M, Rossi D, Murty VV, Zucca E, Gaidano G, Dalla-Favera R, Pasqualucci L, Bhagat G, Bertoni F.

Blood. 2009 May 14;113(20):4918-21. doi: 10.1182/blood-2008-08-174110. Epub 2009 Mar 3.

17.

[TNFAIP3 deletion status in classical Hodgkin lymphoma and its relation to Epstein-Barr virus].

Shi YF, Gao ZF, Liu CL, Li M, Lin DM, Zhou LX, Lai YM, Liu XL, Huang X.

Zhonghua Xue Ye Xue Za Zhi. 2016 Dec 14;37(12):1060-1064. doi: 10.3760/cma.j.issn.0253-2727.2016.12.010. Chinese.

PMID:
28088970
18.

A20 (TNFAIP3) genetic alterations in EBV-associated AIDS-related lymphoma.

Giulino L, Mathew S, Ballon G, Chadburn A, Barouk S, Antonicelli G, Leoncini L, Liu YF, Gogineni S, Tam W, Cesarman E.

Blood. 2011 May 5;117(18):4852-4. doi: 10.1182/blood-2010-10-310995. Epub 2011 Mar 15.

19.

An enhancer element harboring variants associated with systemic lupus erythematosus engages the TNFAIP3 promoter to influence A20 expression.

Wang S, Wen F, Wiley GB, Kinter MT, Gaffney PM.

PLoS Genet. 2013;9(9):e1003750. doi: 10.1371/journal.pgen.1003750. Epub 2013 Sep 5.

20.

A novel A20 (TNFAIP3) antibody (Ber-A20) can be used to detect unmutated A20 by immunohistology.

Hirsch B, Grünbaum M, Wagner F, Bi Y, Lucka L, Du MQ, Stein H, Dürkop H.

Histopathology. 2012 May;60(6B):E19-27. doi: 10.1111/j.1365-2559.2012.04181.x. Epub 2012 Mar 6.

PMID:
22393903

Supplemental Content

Support Center